Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 14/20 | 0.47 |
| ▸ | ESR1 | P03372 | 13/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | ESRRB | O95718 | 1/20 | 0.36 |
| ▸ | ESRRA | P11474 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | FGB | P02675 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.34 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.34 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1119210 | 0.83 | ESR2 (0.50) | ESR2ESR1MEN1KMT2AHSP90AA1 | |
| SCHEMBL1119199 | 0.82 | ESR1 (0.43) | ESR2ESR1MEN1KMT2AHSP90AA1 | |
| SCHEMBL1119206 | 0.82 | ESR2 (0.43) | ESR2ESR1MEN1KMT2AHSP90AA1 | |
| SCHEMBL1119242 | 0.80 | ESR2 (0.47) | ESR2ESR1MEN1KMT2AESRRB | |
| SCHEMBL1119222 | 0.79 | ERN1 (0.49) | ESR2ESR1MEN1KMT2AHSP90AA1 | |
| SCHEMBL1119290 | 0.79 | ESR2 (0.44) | ESR2ESR1MEN1KMT2AHSP90AA1 | |
| SCHEMBL1119215 | 0.79 | MEN1 (0.36) | ESR2ESR1MEN1KMT2AHSP90AA1 | |
| SCHEMBL1119246 | 0.74 | ESR2 (0.38) | ESR2ESR1ESRRBESRRAAR | |
| SCHEMBL1119260 | 0.74 | ESR2 (0.38) | ESR2ESR1ESRRBESRRAALDH1A1 | |
| SCHEMBL1119198 | 0.70 | ESR2 (0.49) | ESR2ESR1MEN1KMT2AESRRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112142-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2011-05-12 | — | — | US | claimed |
| CN-101998852-A | Novel estrogen receptor ligands | KAROBIO AB | 2011-03-30 | — | — | CN | claimed |
| EP-2280699-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2011-02-09 | — | — | EP | claimed |
| WO-2009124968-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2009-10-15 | — | — | WO | claimed |
| US-20110112142-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2011-05-12 | — | — | US | disclosed |
| CN-101998852-A | Novel estrogen receptor ligands | KAROBIO AB | 2011-03-30 | — | — | CN | disclosed |
| EP-2280699-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2011-02-09 | — | — | EP | disclosed |
| WO-2009124968-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112142-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | ESR2, ESR1, ESRRA | ESR2 1/4885ESR1 2/4885MEN1 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.